Dyadic International (DYAI US)

Analysis

Health Care • United States

Dyadic International, Inc. is a global biotechnology company. The Company focuses on improving and applying the proprietary C1 expression system to help drug developers and manufacturers bring biologic drugs to market. Dyadic International focuses on drugs that will improve access and cost to patients as well as save lives.

Refresh

Exchange Announcement • 19 Sep 2026 05:28

424B3 | Prospectus

Exchange Announcement • 12 Sep 2026 05:28

S-1 | IPO Registration

Exchange Announcement • 14 Aug 2026 21:17

Current Report (Form 8-K | Period ending 2026-08-13)

Exchange Announcement • 14 Aug 2026 05:25

424B5 | Prospectus

Exchange Announcement • 12 Aug 2026 20:45

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

424B3 | Prospectus

S-1 | IPO Registration

Current Report (Form 8-K | Period ending 2026-08-13)

424B5 | Prospectus

Quarterly Report (Form 10-Q | Period ending 2026-06-30)